Test characteristics for combining non-invasive liver fibrosis staging modalities in individuals with Hepatitis C...

Area of Science:

• Hepatology
• Diagnostic Accuracy
• Non-invasive Biomarkers

Background:

• Non-invasive methods are preferred over biopsy for advanced fibrosis in Hepatitis C Virus (HCV) patients.
• Current guidelines offer varied testing strategies, necessitating research into optimal approaches.
• Limited data exists on the combined accuracy of multiple non-invasive fibrosis tests.

Purpose of the Study:

• To calculate combined test characteristics for non-invasive fibrosis tests.
• To evaluate the utility of combined testing strategies for advanced fibrosis in HCV.
• To inform optimal methods for identifying advanced fibrosis using non-invasive tests.

Main Methods:

• Synthesized empirical data from fibrosis staging trials and literature.
• Estimated test characteristics for Fibrosis-4 (FIB4), APRI, FibroSure®, and transient elastography (TE).
• Simulated staged and all-inclusive second-test strategies on a population of 10,000.

Main Results:

• Single non-invasive tests showed high Negative Predictive Value (NPV) for cirrhosis (98.2%-99.4%).
• A staged approach using TE as a second test improved sensitivity (93.3%-96.9%) but lowered Positive Predictive Value (PPV) (<32%).
• Combining two non-invasive tests minimally improved NPV and did not significantly alter PPV compared to single tests.

Conclusions:

• Serial non-invasive testing for HCV fibrosis offers limited added value over single tests.
• The utility of combining non-invasive fibrosis tests is questionable due to minimal NPV improvement and potential PPV decrease.
• Calculated combined test characteristics can guide the selection of the best non-invasive methods for advanced fibrosis detection.